80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]鄭 靈,鄭慶偉,溫江妹.同期放化療治療局限期小細胞肺癌患者放療分割模式比較分析[J].福建醫(yī)藥雜志,2021,43(02):24-27.
　ZHENG Ling,ZHENG Qingwei,WEN Jiangmei.Comparison of hyperfractionation and conventional fractionation with concurrent chemoradiotherapy for limited-stage small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2021,43(02):24-27.
點擊復(fù)制

同期放化療治療局限期小細胞肺癌患者放療分割模式比較分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期數(shù):
2021年02期
頁碼:
24-27
欄目:
臨床研究
出版日期:
2021-04-15

文章信息/Info

Title:
Comparison of hyperfractionation and conventional fractionation with concurrent chemoradiotherapy for limited-stage small cell lung cancer
文章編號:
1002-2600(2021)02-0024-04
作者:
鄭 靈; 鄭慶偉; 溫江妹
福建省龍巖市第二醫(yī)院放療科(龍巖 364000)
Author(s):
ZHENG Ling;  ZHENG Qingwei;  WEN Jiangmei
Department of Radiotherapy,the Second Hospital of Longyan,Longyan,Fujian 364000,China
關(guān)鍵詞:
局限期小細胞肺癌;  超分割放療;  化療
Keywords:
limited-stage small cell lung cancer;  hyperfractionated radiotherapy;  chemotherapy
分類號:
R734.2
文獻標志碼:
B
摘要:
目的 觀察同期放化療治療局限期小細胞肺癌放療分割模式選擇的臨床效果。方法 將96例局限期小細胞肺癌患者,隨機分成兩組,化療聯(lián)合同期超分割組(1.5 Gy/次,2次/d,總劑量45 Gy)46例,化療聯(lián)合同期常規(guī)分割組(2 Gy/次,1次/d,總劑量60～66 Gy)50例。化療方案為依托泊苷聯(lián)合順鉑(EP)方案,1～2周期后介入放療,放療采用累及野的三維適形調(diào)強放療,兩組治療后達完全緩解(CR)或近CR者序貫行腦預(yù)防性照射。比較兩組患者的近期臨床療效、不良反應(yīng)和近期生存率。結(jié)果 化療聯(lián)合同期超分割組和化療聯(lián)合同期常規(guī)分割組的局部控制率分別為82.61%和78%,1、2、3年的生存率分別為84.78%、60.87%、36.96%和72.00%、54.00%、34.00%,差異無統(tǒng)計學(xué)意義(P>0.05); 而放射性食道炎分別為32.61%和32.00%,差異無統(tǒng)計學(xué)意義(P>0.05); 放射性肺炎為17.39%和36.00%,差異有統(tǒng)計學(xué)意義(P<0.05); 骨髓抑制主要表現(xiàn)在粒細胞減少,胃腸反應(yīng)主要表現(xiàn)在惡心、嘔吐,兩組發(fā)生率均比較高,差異無統(tǒng)計學(xué)意義(P>0.05)。結(jié)論 化療聯(lián)合同期超分割放療與常規(guī)分割放療治療局限期小細胞肺癌臨床療效相當,不良反應(yīng)患者能耐受,在臨床上均可行。
Abstract:
Objective To observe the clinical effect of simultaneous radiotherapy and chemotherapy in the treatment of limited-stage small cell lung cancer.Methods Nighty-six patients with localized small cell lung cancer were randomly divided into two groups: chemotherapy combined with hyperfractionation group(1.5 Gy/twice a day, total dose 45 Gy)46 cases,and chemotherapy combined with conventional fractionation group(2 Gy/ once a day, total dose 60-66 Gy)50 cases.The chemotherapy regimen was EP regimen.After 1-2 cycles, interventional radiotherapy was used, and the radiotherapy was treated with three-dimensional conformal intensity modulated radiotherapy involving the field.The patients in the two groups who reached CR or near CR after treatment were treated with prophylactic brain irradiation.The short-term clinical efficacy, adverse reactions and short-term survival rate were compared between the two groups.Results The local control rates of chemotherapy combined with hyperfractionation group and chemotherapy combined with conventional fractionation group were 82.61% and 78%, respectively.The 1,2 and 3 year survival rates were 84.78%, 60.87%,and 36.96%, respectively, and 72.00%, 54.00% and 34.00%, respectively.The difference was not statistically significant(P>0.05).The incidence of radiation esophagitis was 32.61% and 32.00% respectively, and the difference was not statistically significant(P>0.05).Radiation pneumonia was 17.39% and 36.00%, respectively.The difference was statistically significant(P<0.05).The main manifestation of myelosuppression is neutropenia.Gastrointestinal reactions were mainly now nausea and vomiting, the incidence of the two groups was relatively high, the difference was not statistically significant(P>0.05). Conclusion The clinical efficacy of chemotherapy combined with hyperfractionated radiotherapy and conventional fractionated radiotherapy is similar to that of conventional fractionated radiotherapy in the treatment of limited-stage small cell lung cancer.The adverse reaction can be tolerated by the patients.Both methods are clinically feasible.

參考文獻/References:

[1] 尤靜,于會明,宋馬小薇,等.局限期小細胞肺癌加速超分割放療同步EP方案化療的劑量遞增I期研究[J].中國肺癌雜志,2017,20(1):55-60.
[2] 王偉力,鐘文,劉大偉,等.胸部放療分割與局限期小細胞肺癌失敗模式的相關(guān)性研究[J].現(xiàn)代腫瘤醫(yī)學(xué),2017,25(2):216-219.
[3] Rodriguez de Dios N,Calvo P,Rico M, et al.Recent developments in radiotherapy for small-cell lung cancer:a review by the oncologic group for the Study of lung cancer(Spanish radiation oncology society)[J].Clin Transl Oncol,2017,19(10):1183-1192.
[4] Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J].N Engl J Med,2002,346(2):85-91.
[5] 殷蔚伯, 谷銑之.腫瘤放射治療學(xué)[M].3版.北京:中國協(xié)和醫(yī)科大學(xué)出版社, 2002: 1108-1111.
[6] 殷蔚伯,余子豪,徐國鎮(zhèn),等.腫瘤放射治療學(xué)[M].4版.北京:中國協(xié)和醫(yī)科大學(xué)出版社,2008:601-608.
[7] Waqar S N,Mrgensztemn D.Treatment advanoes in small cell lung cancer(SCLC)[J]. Pharmacol Ther, 2017, 180: 16-23.
[8] De D,Pijls Johannesma M,Bentzen S M,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].J Clin Oncol, 2006, 24(7): 1057-1063.
[9] 藍柳.局限期小細胞肺癌的胸部放射治療進展[J].癌癥進展,2010,5(8):232.
[10] Censheimer M F,Loo B W.Optimal radiation therapy for smallcell lung cancer[J].Curr yreat Options Onod,2017,18(21):1-9.
[11] Kalemkerian G P.Small cell lung cancer[J].Semin Respir Crit C are Med, 2016,37(5):783-796.
[12] Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer(CONVERT):an open-label,phase3,randomised,superiority trial[J].Lancet Oncol, 2017, 18(8): 1116-1125.
[13] Zhu L,Zhang S,Xu X,et al.Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:a systematic review[J].PLoS One, 2016, 11(5): e0156494.
[14] 劉亞洲,徐海亭,李文廣.同步放化療治療局限期小細胞肺癌療效分析[J].癌癥進展,2007,5(3):393.

更新日期/Last Update: 2021-04-15